SUPERIOR PLATFORM FOR STRUCTURE-BASED DRUG DESIGN
OUR DRUG DISCOVERY ENGINE IS DELIVERING AN EXPANDING PIPELINE OF NOVEL GPCR MODULATORS
OUR TEAM IS COMPOSED OF TALENTED BIOPHARMACEUTICAL PROFESSIONALS AND EXPERT SCIENTISTS
Stabilize. Target. Discover. Transform.
Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible drug targets.
Confo has attracted an international team of accomplished scientists and business professionals to deploy its innovative drug discovery platform on high value GPCR targets. With these valuable resources in place, Confo’s mission is to build a pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments.
“At Confo, our multi-faceted approach to building value starts from our outstanding technology, our stellar team and a growing proprietary pipeline of novel drug candidates. We further validate our approach through strategic partnerships with industry leaders and a strong consortium of global investors.”
Confo Therapeutics Establishes Medical Advisory Board Ghent, Belgium – June 10, 2021 – Confo Therapeutics today announced the establishment of its Medical Advisory Board (MAB). The MAB will provide external review and strategic advice for the company’s clinical development program including the future direction of CFTX-1554, Confo’s lead pre-clinical candidate in neuropathic pain. The international
Confo Therapeutics Awarded EUR 1M VLAIO Grant for Pre-Clinical Development of CFTX-1554, an AT2R Modulator for the Treatment of Neuropathic Pain Ghent, Belgium – March 30, 2021 – Confo Therapeutics announced today that it has been awarded a EUR 1 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will support the pre-clinical development
Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development Ghent, Belgium – October 15, 2020 – Confo Therapeutics today announced the selection of its first preclinical drug candidate, CFTX-1554, a compound designed to address peripheral neuropathic pain with the potential to address additional pain indications. Confo has applied its proprietary, fragment-based
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.